Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Changhao Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9924-9054; OpenAlex author ID A5074431495. Sources: OpenAlex.

Their work

Papers
15 (first author 6, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
39
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 3 papers · 2021: none · 2022: 4 papers · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 15

  1. Correction: circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer. Last author DOI 10.1186/s12943-026-02730-6↗
  2. Endosomal Trafficking Bypassed by the RAB5B-CD109 Interplay Promotes Axonogenesis in KRAS-Mutant Pancreatic Cancer. Co-author DOI 10.1002/advs.202405092↗
  3. Extracellular vesicle-packaged PIAT from cancer-associated fibroblasts drives neural remodeling by mediating m5C modification in pancreatic cancer mouse models. Co-author DOI 10.1126/scitranslmed.adi0178↗
  4. Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-22-3997↗
  5. Corrigendum to "LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9" [Canc. Lett. 410 (2017) 68-81]. First author DOI 10.1016/j.canlet.2022.215836↗
  6. Corrigendum to "Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer" [Canc. Lett. 459(2019)204-215]. Co-author DOI 10.1016/j.canlet.2022.215897↗
  7. KRAS mutant-driven SUMOylation controls extracellular vesicle transmission to trigger lymphangiogenesis in pancreatic cancer. Co-author DOI 10.1172/jci157644↗
  8. Correction: lncRNA-PLACT1 sustains activation of NF-κB pathway through a positive feedback loop with IκBα/E2F1 axis in pancreatic cancer. First author DOI 10.1186/s12943-022-01585-x↗
  9. lncRNA-PLACT1 sustains activation of NF-κB pathway through a positive feedback loop with IκBα/E2F1 axis in pancreatic cancer. First author DOI 10.1186/s12943-020-01153-1↗
  10. Circular RNA circBFAR promotes the progression of pancreatic ductal adenocarcinoma via the miR-34b-5p/MET/Akt axis. Last author DOI 10.1186/s12943-020-01196-4↗
  11. circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer. Last author DOI 10.1186/s12943-020-01205-6↗
  12. Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.06.005↗
  13. LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9. First author DOI 10.1016/j.canlet.2017.09.019↗
  14. HIF-2α regulates non-canonical glutamine metabolism via activation of PI3K/mTORC2 pathway in human pancreatic ductal adenocarcinoma. First author DOI 10.1111/jcmm.13202↗
  15. Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. First author DOI 10.1097/md.0000000000001345↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuming Luo · 8 shared papers, 2020–2026 · strength 1.24
  2. Shangyou Zheng · 9 shared papers, 2017–2024 · strength 1.07
  3. Zhihua Li · 7 shared papers, 2015–2026 · strength 0.83
  4. Rufu Chen · 6 shared papers, 2015–2026 · strength 0.83
  5. Yao Kong · 5 shared papers, 2020–2026 · strength 0.80
  6. Huilin Ye · 7 shared papers, 2017–2022 · strength 0.72
  7. Zhiqiang Fu · 7 shared papers, 2017–2022 · strength 0.69
  8. Quanbo Zhou · 5 shared papers, 2017–2022 · strength 0.51
  9. Xiaofeng Guo · 3 shared papers, 2020–2026 · strength 0.50
  10. Jiabin Yang · 3 shared papers, 2022–2024 · strength 0.49
  11. Dingwen Zhang · 3 shared papers, 2022–2024 · strength 0.49
  12. Rufu Chen · 4 shared papers, 2017–2022 · strength 0.47
  13. Guolin Li · 3 shared papers, 2019–2024 · strength 0.41
  14. Rufu Chen · 3 shared papers, 2020–2024 · strength 0.40
  15. Y P. Li · 1 shared paper, 2026 · strength 0.29
  16. Lusheng Wei · 3 shared papers, 2017–2022 · strength 0.28
  17. Xiaofan Ren · 2 shared papers, 2020–2022 · strength 0.25
  18. Mingyang Liu · 2 shared papers, 2020–2022 · strength 0.25
  19. Yu Zhou · 2 shared papers, 2015–2024 · strength 0.24
  20. Chonghui Hu · 2 shared papers, 2019–2022 · strength 0.22
  21. Bin Zhang · 2 shared papers, 2019–2022 · strength 0.22
  22. Xiaohui Zhao · 2 shared papers, 2017–2022 · strength 0.19
  23. Yue Zhao · 2 shared papers, 2017–2022 · strength 0.19
  24. Tianhao Huang · 1 shared paper, 2024 · strength 0.19
  25. Zhuo Kui Wu · 1 shared paper, 2024 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.